Amerikanische Gesellschaft für Hirudotherapie

Valstybinė vaistų kontrolės tarnyba — State Medicines Control Agency of Lithuania

VVKT · Lithuania · europe

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

Lithuania's State Medicines Control Agency — leeches fall under EU medical-device frameworks (MDR 2017/745) as implemented through Lithuanian national law; leech-specific national authorisation has not been independently verified by ASH.

Regulatory Profile

Agency type
national regulator
Region
europe
Country
Lithuania
Leech status
unregulated
Last ASH review
2026-05-26

Relevant Regulation Codes

  • Lithuanian Law on Pharmacy
  • EU Medical Device Regulation (MDR) 2017/745 — as transposed into Lithuanian law
  • Lithuanian Law on the Health System

Prescriber Requirements

  • Lithuanian Medical Association–registered physician — order required for any biomedical device application
  • Allied health professional application under physician supervision per institutional protocol

Supply Chain & GMP

VVKT registration as applicable; Lithuanian-language labelling required by national law. Standard cold-chain conditions; EU intra-community movement under MDR applies.

Import/Export Rules

Free movement within the EU single market under MDR; State Food and Veterinary Service clearance for live invertebrates from non-EU origin; CITES Appendix II paperwork for Hirudo medicinalis / verbana on extra-EU import.

Reimbursement Context

National Health Insurance Fund (VLK) coverage depends on inpatient bundling; outpatient hirudotherapy is generally not separately reimbursed.

ASH Editorial Notes

Leech-specific pathway not independently verified by ASH; falls under general EU MDR framework as transposed into Lithuanian law. VVKT coordinates with EMA and other EU NCAs; whether leech-specific guidance exists has not been independently mapped by ASH.

Related Jurisdictions

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.